



## Immuron CEO, Steven Lydeamore to present at AusBioInvest

Melbourne, Australia, October 30, 2023: Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to advise our Chief Executive Officer, Steven Lydeamore will be presenting at AusBioInvest 2023 on Monday, October 30th in the 9.40am – 10.35am session (AEST) at the Park Hyatt, Melbourne, Australia.

A copy of the presentation being made at AusBioInvest 2023 is included below.

This release has been authorised by the directors of Immuron Limited.

--- END ---

### COMPANY CONTACT:

**Steven Lydeamore**

Chief Executive Officer

Ph: +61 (0)3 9824 5254

info@immuron.com

### About Travelan®

Travelan® is an orally administered passive immunotherapy that prophylactically reduces the likelihood of contracting traveller's diarrhoea, a digestive tract disorder that is commonly caused by pathogenic bacteria and the toxins they produce. Travelan® is a highly purified tabletised preparation of hyperimmune bovine antibodies and other factors, which when taken with meals bind to diarrhoea-causing bacteria and prevent colonisation and the pathology associated with traveller's diarrhoea. In Australia, Travelan® is a listed medicine on the Australian Register for Therapeutic Goods (AUST L 106709) and is indicated to reduce the risk of Traveller's Diarrhoea, reduce the risk of minor gastrointestinal disorders and is antimicrobial. In Canada, Travelan® is a licensed natural health product (NPN 80046016) and is indicated to reduce the risk of Traveller's Diarrhoea. In the U.S., Travelan® is sold as a dietary supplement for digestive tract protection.

### About Traveller's Diarrhoea

Traveller's Diarrhoea is a gastrointestinal infection with symptoms that include loose, watery (and occasionally bloody) stools, abdominal cramping, bloating, and fever. Enteropathogenic bacteria are responsible for most cases, with enterotoxigenic *Escherichia coli* (ETEC) playing a dominant causative role. Campylobacter spp. are also responsible for a significant proportion of cases. The more serious infections with Salmonella spp. the bacillary dysentery organisms belonging to Shigella spp. and Vibrio spp. (the causative agent of cholera) are often confused with Traveller's Diarrhoea as they may be contracted while travelling and initial symptoms are often indistinguishable.



**About Immuron**

Immuron Limited (ASX: IMC, NASDAQ: IMRN), is an Australian biopharmaceutical company focused on developing and commercialising orally delivered targeted polyclonal antibodies for the treatment of infectious diseases.

For more information visit: <http://www.immuron.com>

**FORWARD-LOOKING STATEMENTS:**

This press release may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. Such statements include, but are not limited to, any statements relating to our growth strategy and product development programs and any other statements that are not historical facts. Forward-looking statements are based on management’s current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock value. Factors that could cause actual results to differ materially from those currently anticipated include: risks relating to our growth strategy; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; risks relating to the results of research and development activities; risks relating to the timing of starting and completing clinical trials; uncertainties relating to preclinical and clinical testing; our dependence on third-party suppliers; our ability to attract, integrate and retain key personnel; the early stage of products under development; our need for substantial additional funds; government regulation; patent and intellectual property matters; competition; as well as other risks described in our SEC filings. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law.



## **AUSBIOINVEST PRESENTATION**

---

30 OCTOBER, 2023

Steven Lydeamore - CEO

NASDAQ: IMRN

ASX: IMC

# SAFE HARBOR STATEMENT

Certain statements made in this presentation are forward-looking statements and are based on Immuron's current expectations, estimates and projections. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," "guidance" and similar expressions are intended to identify forward-looking statements.

Although Immuron believes the forward-looking statements are based on reasonable assumptions, they are subject to certain risks and uncertainties, some of which are beyond Immuron's control, including those risks or uncertainties inherent in the process of both developing and commercializing technology. As a result, actual results could materially differ from those expressed or forecasted in the forward-looking statements.

The forward-looking statements made in this presentation relate only to events as of the date on which the statements are made. Immuron will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances or unanticipated events occurring after the date of this presentation except as required by law or by any appropriate regulatory authority.

FY2024 results in this presentation are subject to audit review.





# REVENUE GENERATING WITH STRONG PIPELINE

Immuron Ltd (NASDAQ:IMRN) (ASX:IMC) is a globally integrated biopharmaceutical company focused on developing, and commercialising, oral immunotherapeutics for the treatment of gut mediated diseases

## Financial Snapshot

Shares on Issue	227,798,346
Total Options	14,568,559
Last Traded Price	IMC: A\$0.075
52 week High/Low	IMC: A\$0.105 / 0.067 IMRN: \$3.21 / 1.39
Market Cap	IMC: A\$17.08m
Cash & Cash Equivalents (30 June 2023)	A\$17.2m

## Major Shareholders


Holder	Units	% of CSO
BNY Mellon Asset Management	78,704,665	34.6 %
<b>Management &amp; Board</b>	<b>6,904,554</b>	<b>3.0 %</b>
Authentic Australia Pty. Ltd.	6,000,000	2.6 %
Grandlodge	3,846,712	1.7 %



# TECHNOLOGY PLATFORM FOR GUT MEDIATED DISEASES

Bovine colostrum is the first milk of cows after calving. It is rich in immunoglobulins, lactoferrin, lysozyme, lactoperoxidase, growth factors and bioactive peptides. Colostrum has higher levels of protein, fat, vitamins, and minerals when compared to milk. This enables full development of the newborn calf in addition to immunity against several pathogens.\*

Immuron's proprietary technology platform ***combines the natural human nutrition & health benefits of bovine colostrum with a novel class of specifically targeted oral polyclonal antibodies*** that offer delivery within the gastrointestinal ("GI") tract and can be used to target viruses or bacteria and neutralize the toxins they produce at mucosal surfaces.





- ✓ Reduce occurrence and reduce/relieve diarrhoea
- ✓ Reduce/relieve abdominal cramping
- ✓ Reduce/relieve gastrointestinal pain
- ✓ Assists repair of gastrointestinal/gut wall lining
- ✓ Enhance/promote immune defence
- ✓ Enhance/promote health liver function

***Australian Permitted indications; these statements have not been evaluated by the Food and Drug Administration (FDA)***

# STRONG PIPELINE WITH NEAR TERM MILESTONES



## Immuron's Clinical Programs


Compound or brand name	Indication	Phase I	Phase II	Phase III	Market
IMM-124E Travelan®	Traveler's Diarrhea ETEC challenge				
IMM-529	<i>Clostridioides difficile</i> Infection & Recurrence				

## Our Partners' Clinical Programs

Compound or brand name	Partner	Phase I	Phase II	Phase III	Market
Travelan®					
CampETEC					



# STRONG SALES GROWTH IN ATTRACTIVE MARKET



## Traveller's Diarrhoea (TD)

Market is large and growing ~7%<sup>3</sup> CAGR



## Industry tailwinds

Travel picking up significantly following COVID lockdowns



## Frequent

30% - 70% of travelers experience TD<sup>4</sup>



### Net Sales

FY23: **A\$1.16 million**

1QFY24: **A\$1.35 million**

**229%** higher than pre-pandemic period  
1QFY20



### Net Sales

FY23: **A\$0.64 million**

1QFY24: **A\$0.21 million**

**9%** lower than pre-pandemic period  
1QFY20

### Australia

12 months to July 2023  
short term resident  
returns **77%** of those  
in 2019<sup>1</sup>

### USA

Total departures  
June 2023 **99.4%**  
of June 2019<sup>2</sup>



Chief Commercial  
Officer has 20+ year's  
experience with local  
and global (Asia, UK)  
commercial leadership  
roles with GSK and  
P&G

**\$83m**

Based on US annual  
travel numbers and a  
penetration rate of  
15%, **the market  
potential is estimated  
at \$83m<sup>5</sup>**

**\$50m**

Based on EU travel  
numbers and a  
penetration rate of  
15%, the **market  
potential is estimated  
at \$50m<sup>5</sup>**

1. <https://www.abs.gov.au/statistics/industry/tourism-and-transport/overseas-arrivals-and-departures-australia/latest-release>

2. <https://www.trade.gov/sites/default/files/2023-09/US-Outbound-to-World-Regions.xlsx>

3. Research Reports World, 28 May 2021: Global Traveler's Diarrhea Therapeutics Industry Research Report, Growth Trends and Competitive Analysis 2021-2027

4. Centers for Disease Control and Prevention Yellow Book

5. IMC Company Report - Travelan Market Analysis 2019

# VALUABLE SALES POTENTIAL FOR PIPELINE PRODUCTS



## Lumanity\* Opportunity Assessment for IMM-124E

- › Immuron's development of **IMM-124E** (hyperimmune bovine colostrum) as a prescription medication has the potential to address this unmet need
- › Primary care physicians (PCP)s impressed with clinical efficacy endpoint targets demonstrating > 80% protection against the development of diarrhea.
- › If base case efficacy targets are reached, IMM-124E would mostly be used by travelers going to the highest risk areas (e.g., rural Central America/Asia/Africa).
- › Based on the estimated market size and pricing, the base case yearly revenue in USA for IMM-124E is projected at **US\$102M**.
- › Reaching higher efficacy goals could broaden use.

## Lumanity Opportunity Assessment for IMM-529

- › Infectious disease experts reacted favorably to the **IMM-529** MOA, and its unique ability to target three elements of the rCDI infection – the spores, vegetative cells, and Toxin B
- › Non-microbiome approaches (such as IMM-529) are still appealing to experts, who noted that clinical trial efficacy (reduction in relapse rate) and cost/access will be the key drivers of clinical use in recurrent patients, not mechanism of action
- › Based on the estimated market size, anticipated payer restrictions, pricing, and competition, base case yearly revenue in USA for IMM-529 is conservatively projected at **US\$93M** for the target patient population (limited to 2nd recurrence and later based on trial design and payer coverage)
- › Positioning IMM-529 earlier than second recurrence and/or efficacy targets could lead to higher uptake.

Compound or brand name

Indication

Phase I

Phase II

Phase III

Market

**IMM-124E - Travelan®**

Traveler's Diarrhea ETEC challenge

**Immuron**

**IMM-529**

*Clostridioides difficile* Infection & Recurrence

**Immuron**



# NEAR TERM MILESTONES ANTICIPATED TO DRIVE VALUE

	2H 2022	1H 2023	2H 2023	1H 2024
Travelan®	<ul style="list-style-type: none"> <li>FDA IND<sup>1</sup> approved for single daily dose IMM-124E ETEC<sup>2</sup> CHIM<sup>3</sup> clinical trial</li> </ul>	<ul style="list-style-type: none"> <li>IRB Approval<sup>4</sup></li> <li>Initiated IMM-124E ETEC<sup>2</sup> CHIM<sup>3</sup> clinical trial</li> </ul>	<ul style="list-style-type: none"> <li>100% of patients enrolled</li> <li>Completion of In-patient phase ETEC<sup>2</sup> CHIM<sup>3</sup> clinical trial</li> </ul>	<ul style="list-style-type: none"> <li>Topline results for IMM-124E ETEC<sup>2</sup> clinical trial</li> <li>Clinical Study Report</li> </ul>
CampETEC	<ul style="list-style-type: none"> <li>Submitted Response Letter to FDA Clinical Hold</li> <li>Immuron sponsored Toxicology study - completed</li> </ul>	<ul style="list-style-type: none"> <li>Toxicology Study Report</li> <li>FDA IND<sup>1</sup> approved (Clinical Hold released)</li> </ul>	<ul style="list-style-type: none"> <li>Institutional Review Board approval of NMRC<sup>5</sup> CampETEC Campylobacter CHIM<sup>3</sup> clinical trial protocol</li> <li>FDA approval of IND amendment for change to protocol</li> </ul>	<ul style="list-style-type: none"> <li>Initiate NMRC<sup>5</sup> CampETEC Campylobacter CHIM<sup>3</sup> clinical trial</li> <li>Completion of In-patient phase CampETEC Campylobacter CHIM<sup>3</sup> clinical trial</li> </ul>
IMM-529	<ul style="list-style-type: none"> <li>600 mg solid dose active formulation development</li> </ul>		<ul style="list-style-type: none"> <li>IMM-529 cGMP manufacture</li> </ul>	<ul style="list-style-type: none"> <li>IMM-529 (CDI)<sup>7</sup> Pre-IND<sup>1</sup> submission</li> </ul>
Travelan®	<ul style="list-style-type: none"> <li>USU<sup>6</sup> P2TD IMM-124E field clinical trial recruitment commencement</li> </ul>		<ul style="list-style-type: none"> <li>~50% of 868 participants recruited</li> </ul>	<ul style="list-style-type: none"> <li>Completion of enrollment</li> <li>Completion of in-patient phase</li> </ul>



**STEVEN LYDEAMORE  
CHIEF EXECUTIVE OFFICER  
IMMURON LIMITED**

**CONTACT INFORMATION:**

---



EMAIL: [STEVE@IMMURON.COM](mailto:STEVE@IMMURON.COM)



PHONE: AUSTRALIA: +613 8892 4854

# SCIENTIFIC REFERENCES



## Travelan® (IMM-124E)

Travelan® has been shown to reduce both the incidence and severity of ETEC-induced diarrhea in up to 90% of volunteers	<a href="#">Scandinavian Journal of Gastroenterology, 46:7-8, 862-868, DOI: 10.3109/00365521.2011.574726</a>
Clinical Evaluation of Travelan® an Oral Prophylactic for Prevention of Travelers' Diarrhea in Active Duty Military Service Assigned Abroad.	<a href="#">Military Health System Research Symposium 14-17 Aug 2023 Abstract 1</a>
Travelan as a broad Spectrum anti-bacterial	<a href="#">Immuron Limited, 29 April, 2011</a>
Travelan® demonstrates broad reactivity to Vibrio cholera strains from Southeast Asia indicating broad potential for prevention of traveler's diarrhea	<a href="#">US Department of Defense, Armed Forces Research Institute of Medical Sciences (AFRIM), 4 September, 2019</a>
Travelan® prevented clinical shigellosis (bacillary dysentery) in 75% of Travelan® treated animals compared to placebo and demonstrated a significant clinical benefit	<a href="#">US Department of Defense, Armed Forces Research Institute of Medical Sciences (AFRIM), 5 September, 2018</a>
Travelan® able to bind and was reactive to 60 clinical isolates of each bacteria, Campylobacter, ETEC, and Shigella	<a href="#">US Department of Defense, Armed Forces Research Institute of Medical Sciences (AFRIM), 30 January, 2017</a>
Efficacy of hyperimmune bovine colostrum against shigellosis in rhesus macaque (Macaca mulatta), and bioactivity of HBC against common enteric pathogens	<a href="#">Islam et al., 2020. Submitted to mSphere, American Society for Microbiology</a>
Bioactive Immune Components of Travelan®	<a href="#">Clin Vaccine Immunol 24:e00186-16. https://doi.org/10.1128/CVI.00186-16</a>
Hyperimmune bovine colostrum containing lipopolysaccharide antibodies (IMM-124E) has a non-detrimental effect on gut microbial communities in unchallenged mice	<a href="#">Rachele Gore, Mitra Mohsenipour, Jennifer L Wood, Gayathri K Balasuriya, Elisa L Hill-Yardin, Ashley E Franks</a>
Administration of the Hyper-immune Bovine Colostrum Extract IMM-124E Ameliorates Experimental Murine Colitis	<a href="#">Journal of Crohn's and Colitis, Volume 13, Issue 6, June 2019, Pages 785–797, https://doi.org/10.1093/ecco-jcc/ijy213</a>

## IMM-529

Bovine antibodies targeting primary and recurrent Clostridium difficile disease are a potent antibiotic alternative	<a href="#">Sci Rep 7, 3665 (2017). https://doi.org/10.1038/s41598-017-03982-5</a>
---	--